{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:32:56Z","timestamp":1793374376691,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":661,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1093\/annonc\/mdx702","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T19:49:05Z","timestamp":1513885745000},"page":"i3-i9","source":"Crossref","is-referenced-by-count":355,"special_numbering":"S1","title":["Overview of current systemic management of EGFR-mutant NSCLC"],"prefix":"10.1016","volume":"29","author":[{"given":"W.-H.","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.-H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.S.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx702_bb0010","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdx702_bb0015","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"5676","key":"10.1093\/annonc\/mdx702_bb0020","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"1","key":"10.1093\/annonc\/mdx702_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdx702_bb0030","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1093\/annonc\/mdx702_bb0035","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx702_bb0040","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdx702_bb0045","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"10.1093\/annonc\/mdx702_bb0050","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1158\/1078-0432.CCR-07-5123","article-title":"Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdx702_bb0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"56","key":"10.1093\/annonc\/mdx702_bb0060","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1038\/sj.onc.1204102","article-title":"From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents","volume":"19","author":"Morin","year":"2000","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdx702_bb0065","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue","year":"2009","journal-title":"J Ciln Oncol"},{"key":"10.1093\/annonc\/mdx702_bb0070","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2007.15.6695","article-title":"Specific EGFR mutations predict treatment outcome of stage IIIB\/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy","volume":"26","author":"Yang","year":"2008","journal-title":"J Ciln Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdx702_bb0075","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ejca.2015.06.120","article-title":"A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911","volume":"51","author":"Yamada","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdx702_bb0080","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjc.6603393","article-title":"A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations","volume":"95","author":"Asahina","year":"2006","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1093\/annonc\/mdx702_bb0085","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jama.2014.3314","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis","volume":"311","author":"Lee","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1093\/annonc\/mdx702_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdx702_bb0095","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdx702_bb0100","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdx702_bb0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdx702_bb0110","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdx702_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw279","article-title":"Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival","volume":"109","author":"Lee","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"34","key":"10.1093\/annonc\/mdx702_bb0120","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"issue":"24","key":"10.1093\/annonc\/mdx702_bb0125","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res"},{"issue":"16","key":"10.1093\/annonc\/mdx702_bb0130","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/onc.2009.526","article-title":"Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor","volume":"29","author":"Ercan","year":"2010","journal-title":"Oncogene"},{"issue":"5","key":"10.1093\/annonc\/mdx702_bb0135","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdx702_bb0140","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S1470-2045(14)70472-3","article-title":"Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial","volume":"15","author":"Ellis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx702_bb0145","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1093\/annonc\/mdx702_bb0150","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","article-title":"Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin\/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations","volume":"31","author":"Yang","year":"2013","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1093\/annonc\/mdx702_bb0155","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L","volume":"34","author":"Urata","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdx702_bb0160","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdx702_bb0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann Oncol"},{"issue":"18 Suppl","key":"10.1093\/annonc\/mdx702_bb0170","doi-asserted-by":"crossref","first-page":"LBA9007","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA9007","article-title":"Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): a randomized, open-label phase III trial","volume":"35","author":"Mok","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdx702_bb0175","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdw322","article-title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials","volume":"27","author":"Yang","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdx702_bb0180","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/jjco\/hys042","article-title":"Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC","volume":"42","author":"Takeda","year":"2012","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdx702_bb0185","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17425255.2016.1190831","article-title":"Hepatotoxicity of targeted therapy for cancer","volume":"12","author":"Lee","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1093\/annonc\/mdx702_bb0190","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2006.05.7109","article-title":"Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration","volume":"24","author":"Seki","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdx702_bb0195","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","article-title":"First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases","volume":"11","author":"Schuler","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx702_bb0200","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis","volume":"35","author":"Magnuson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdx702_bb0205","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1200\/JCO.2016.71.5706","article-title":"Epidermal growth factor receptor mutations in non-small-cell lung cancer with brain metastasis: can up-front radiation therapy be deferred or withheld?","volume":"35","author":"Zhou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdx702_bb0210","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx702_bb0215","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","article-title":"Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase Inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis","volume":"33","author":"Lee","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx702_bb0220","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","article-title":"Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer","volume":"30","author":"Su","year":"2012","journal-title":"Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdx702_bb0225","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdx702_bb0230","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I Mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdx702_bb0235","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Lee","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx702_bb0240","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1200\/JCO.2016.66.9218","article-title":"Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations","volume":"34","author":"Cheng","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdx702_bb0245","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx702_bb0250","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Masters","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdx702_bb0255","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer\u2014a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdx702_bb0260","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdx702_bb0265","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","article-title":"Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)","volume":"26","author":"Zhou","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdx702_bb0270","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419316680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419316680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/suppl_1\/i3\/23947302\/mdx702.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T03:33:49Z","timestamp":1582169629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419316680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":53,"alternative-id":["S0923753419316680"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx702","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}